MX2015007971A - Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina. - Google Patents

Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina.

Info

Publication number
MX2015007971A
MX2015007971A MX2015007971A MX2015007971A MX2015007971A MX 2015007971 A MX2015007971 A MX 2015007971A MX 2015007971 A MX2015007971 A MX 2015007971A MX 2015007971 A MX2015007971 A MX 2015007971A MX 2015007971 A MX2015007971 A MX 2015007971A
Authority
MX
Mexico
Prior art keywords
body weight
insulin resistance
weight gain
treating
bifidobacterium animalis
Prior art date
Application number
MX2015007971A
Other languages
English (en)
Inventor
Liping Zhao
Jian Shen
Jingjing Wang
Martin Saul Obin
Muriel Derrien
Emilie Rocher
Johan Van Hylckama Vlieg
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of MX2015007971A publication Critical patent/MX2015007971A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)

Abstract

El presente invento se refiere a la utilización de la cepa CNCM I-2494 de Bifidobacterium animalis subsp. lactis, para el uso en la disminución de la ganancia de peso corporal inducida por la dieta y el mejoramiento de la resistencia a la insulina inducida por la dieta, en un sujeto de experimentación.
MX2015007971A 2012-12-20 2012-12-20 Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina. MX2015007971A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/087043 WO2014094279A1 (en) 2012-12-20 2012-12-20 Use of bifidobacterium animalis for treating or preventing body weight gain and insulin resistance

Publications (1)

Publication Number Publication Date
MX2015007971A true MX2015007971A (es) 2016-03-09

Family

ID=50977567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007971A MX2015007971A (es) 2012-12-20 2012-12-20 Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina.

Country Status (10)

Country Link
US (1) US20150328266A1 (es)
EP (1) EP2935560A4 (es)
JP (1) JP6101818B2 (es)
CN (1) CN104884610A (es)
AR (1) AR094025A1 (es)
BR (1) BR112015014693A2 (es)
CA (1) CA2895963A1 (es)
MX (1) MX2015007971A (es)
RU (1) RU2015129066A (es)
WO (1) WO2014094279A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018005863B1 (pt) * 2015-09-24 2024-02-27 Agriculture Victoria Services Pty Ltd Método para isolamento, seleção e/ou caracterização de uma linhagem endofítica
KR20180129944A (ko) * 2016-04-14 2018-12-05 듀폰 뉴트리션 바이오사이언시즈 에이피에스 식품, 에너지 및/또는 지방 섭취 감소를 위한 비피더스균
BR112018070512A2 (pt) * 2016-04-14 2019-01-29 Dupont Nutrition Biosci Aps composição, usos de uma composição e método para aumentar a massa corporal magra
CN105853466B (zh) * 2016-05-06 2018-08-24 中国农业大学 双歧杆菌在制备用于预防和/或治疗因摄入酒精造成体重减轻的产品中的应用
BE1025428B1 (nl) * 2018-01-23 2019-02-14 Omega Pharma Innovation & Development Nv Voedingssupplement en gebruiken daarvan
CN109486715B (zh) * 2018-12-07 2022-07-15 江苏靶标生物医药研究所有限公司 一种富硒长双歧杆菌及其制备方法和应用
CN110923166A (zh) * 2019-12-11 2020-03-27 石家庄君乐宝乳业有限公司 动物双歧杆菌乳亚种jmcc0025、其分离纯化方法及应用
BR112022021309A2 (pt) * 2020-04-27 2022-12-06 Gervais Danone Sa Metabólitos de aminoácidos de cadeia ramificada e composição
CN113197311B (zh) * 2020-07-03 2023-06-23 内蒙古蒙牛乳业（集团）股份有限公司 一种乳酸菌组合物及其制备方法
CN113207961B (zh) * 2020-09-29 2023-06-23 内蒙古蒙牛乳业（集团）股份有限公司 乳双歧杆菌MN-Gup乳制品及其在改善2型糖尿病中应用
CN113197921B (zh) * 2020-09-29 2023-05-12 内蒙古蒙牛乳业（集团）股份有限公司 乳双歧杆菌MN-Gup及其菌剂在治疗2型糖尿病中的应用
CN113142303A (zh) * 2021-01-18 2021-07-23 重庆市天友乳业股份有限公司 一种具有预防肥胖功效的酸奶及其制备方法
CN113018319A (zh) * 2021-01-21 2021-06-25 中南大学 一种用于缓解因长期低剂量辐射暴露所致胰岛素抵抗的复合菌剂及其应用
CN112980725B (zh) * 2021-02-10 2022-11-11 中科微智（北京）生物科技有限公司 一种乳双歧杆菌及其在促进儿童青少年生长发育中的用途
WO2023068279A1 (ja) * 2021-10-18 2023-04-27 国立研究開発法人医薬基盤・健康・栄養研究所 ブラウチア（Ｂｌａｕｔｉａ）属細菌のスクリーニング方法
CN114350547B (zh) * 2021-12-17 2023-05-16 四川省医学科学院·四川省人民医院 一种乳双歧杆菌菌株b-622及其在制备治疗糖尿病药物中的应用
CN114480229B (zh) * 2022-04-15 2022-08-09 微康益生菌(苏州)股份有限公司 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2811333B1 (fr) * 2000-07-04 2003-01-10 Gervais Danone Sa Microorganismes ayant une action modulatrice de la glycosylation de surface des cellules intestinales et methode de selection desdits microorganismes
US20060228448A1 (en) * 2005-04-11 2006-10-12 The Iams Company Pet food compositions comprising two components
CN102046189B (zh) * 2008-05-26 2013-11-13 达能日尔维公司 动物双歧杆菌在制备非治疗性组合物中的用途
ES2729765T3 (es) * 2009-06-19 2019-11-06 Dupont Nutrition Biosci Aps Bifidobacterias para el tratamiento de la insuficiencia cardíaca congestiva
BR112012010398A2 (pt) * 2009-11-02 2016-07-12 Gervais Danone Sa metodo para reduzir a inflamação gastrointestinal usando a bactéria bifidobacterium animalis ou um produto laticínio fermentado compreendendo tal bactéria

Also Published As

Publication number Publication date
EP2935560A4 (en) 2016-08-31
JP2016510311A (ja) 2016-04-07
JP6101818B2 (ja) 2017-03-22
US20150328266A1 (en) 2015-11-19
AR094025A1 (es) 2015-07-08
BR112015014693A2 (pt) 2017-10-10
EP2935560A1 (en) 2015-10-28
RU2015129066A (ru) 2017-01-23
CN104884610A (zh) 2015-09-02
CA2895963A1 (en) 2014-06-26
WO2014094279A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX2015007971A (es) Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina.
HK1226100B (zh) 雙歧桿菌乳酸亞種(bifidobacterium animalis subsp．lactis)cect 8145的新菌株及其用於治療和/或預防超重和肥胖症以及相關疾病的用途
SG10202112104UA (en) Lactobacillus paracasei strain and use thereof
PT2626076T (pt) Utilizações terapêuticas de lactobacillus salivarus ls01 22775
HK1204869A1 (en) Probiotic derived non-viable material for infection prevention and treatment
MX2015005898A (es) Uso de una cepa de lactobacillus rhamnosus para reducir la ganancia de peso o la resistencia a la insulina, o ambas cosas al mismo tiempo.
PL3016667T3 (pl) Probiotyczne szczepy bakteryjne do zapobiegania i leczenia chorób w jamie ustnej
MX2011008398A (es) Lactobacillus helveticus cncm i-4095 y el control del peso.
HK1198326A1 (zh) 用於預防或治療上呼吸道感染的鼠李糖乳桿菌和動物雙歧桿菌乳亞種
MX2011008400A (es) Lactobacillus rhamnosus cncm i-4096 y el control del peso.
HK1209780A1 (en) Non-pathogenic f18 e. coli strain and use thereof f18
PL2568815T3 (pl) Fermentacja synergistyczna lactobacillus rhamnosus i lactobacillus paracasei podgatunek paracasei
EP2992765C0 (en) CLOSED SOY MILK WITH STREPTOCOCCUS THERMOPHILUS AND LACTOBACILLUS BULGARICUS
SG11201504542PA (en) Probiotic strains for the treatment and/or prevention of diarrhœa
PL2707476T3 (pl) Szczep lactobacillus fermentum cect 7472 o właściwościach probiotycznych
ZA201208978B (en) Probiotic strains for use in improving transepithelial resistance
MX2015005897A (es) Cepa de lactobacillus rhamnosus para reducir la acumulacion de grasa corporal.
ZA201304460B (en) Novel bacterium and extracts of said bacterium and the use of same in therapy
WO2014096083A3 (fr) Utilisation de microorganismes probiotiques comme agent favorisant la synthèse de mélanine
MX2014001572A (es) Nueva cepa de l.bulgaricus con capacidad de inhibir la adhesion de cepas de h. pylori a celulas epiteliales.
LT2914754T (lt) Lactobacillus delbrueckii bakterijų nauja padermė ir jos panaudojimas bičių duonelės gamybai
RS20100436A3 (en) Indigenous LACTOBACILLUS strains and their use as probiotics
Patel et al. the efficacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation.
AU340719S (en) Inflatable half ball chair on gas lift and castors
UA96709C2 (ru) Штамм реликтовых бактерий bacillus sp. f, который имеет иммуномодулирующую активность и геропротекторной способность